CSC Financial: AI is accelerating the reshaping of traditional pharmaceutical R&D paradigms.

CSC Financial's research report states that AI is accelerating the reshaping of traditional pharmaceutical R&D paradigms. Drug action is essentially the interaction between molecules and targets in the body, and traditional drug R&D faces the underlying pain point of Eroom's Law. AI technology has fully penetrated core areas such as target identification, virtual screening, de novo design, ADMET prediction, and automated synthesis, effectively breaking through the throughput limits of high-throughput physical blind screening faced in traditional pharmaceutical R&D, and significantly improving pharmaceutical efficiency and success rates.